Merck (MRK) Reports FDA Approval of KEYTRUDA (pembrolizumab) in Combination With Inlyta®= (axitinib)

April 22, 2019 6:46 AM
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles